Tag: Umang Vohra
Digitalization in pharma operations inevitable but challenges remain: Top CEOs
Industry captains and regulators in the ecosystem deliberate on achieving excellence and quality in operations, vaccine development and sustainability
Cipla ranked as one of most sustainable healthcare companies in DJSI
As of November 12, 2021, Cipla performed in the top decile in the pharmaceutical Industry in the S&P Global Corporate Sustainability Assessment, with a ranking of 93 percentile in the industry, meaning 93% of companies reached an equal or lower ESG Score..................
Cipla signs licensing deal with Lilly to expand access to COVID-19...
Baricitinib was issued a restricted emergency use approval by the CDSCO, Ministry of Health, India for use in combination with Remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in hospitalized adults..........................
Cipla signs COVID-19 drug licensing deal with MSD
Cipla enters into a licensing agreement with MSD to expand access to the investigational oral therapeutic drug for COVID-19 treatment...........................
Cipla pledges support to ‘Terra Carta’, for a sustainable future
Cipla is the only Indian pharmaceutical company to join this global sustainability initiative........................
Cipla EU & Jiangsu Acebright enter into a joint venture
According to the agreement, Cipla EU will hold an 80% stake and Acebright will hold a 20% stake in it for a combined investment of USD 30mn. Upon incorporation, the JV Co will set up a manufacturing facility for local manufacture of respiratory products.............
Cipla appoints Dr Raju Mistry as Global Chief People Officer
In her role at Cipla, Raju will oversee Human Resources, and Administration and Facilities Management......................
InvaGen to acquire Avenue Therapeutics for specialty hospital business in the...
At the first stage closing, InvaGen or its affiliates will acquire, through the issuance by Avenue of new shares, shares representing a 33.3% stake in Avenue’s capital stock on a fully diluted basis for $35 million...…………...
Serum Institute, Cipla launch Hepatitis B vaccine in India
Under a co-exclusive agreement with Serum Institute of India (SII), global pharmaceutical company Cipla has launched adult Hepatitis B vaccine in India.....